A majority of respondents (82.6%) would perform serum anti-PLA2R antibody testing when nephrotic syndrome is present or when the patient has > 3.5 g proteinuria (spot or 24-h urine) without nephrotic syndrome (68.1%). Overall 33.3% would order the serum anti-PLA2R antibody test when there is > 1 g proteinuria per day (spot test or 24 h urine), and 8.7% would check only after a kidney biopsy has confirmed PLA2R-positive MN. Here, PLA2R1 is linked to nephrotic syndrome.